Ghost Tree Capital, LLC Argenx Se Transaction History

Ghost Tree Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $4.24 Million - $6.33 Million	12,500 Added 500.0%	15,000 $5.71 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $923,375 - $1.37 Million	2,500 New	2,500 $1.23 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $5.33 Million - $8.21 Million	-50,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $5.67 Million - $7.53 Million	-50,000 Reduced 50.0%	50,000 $5.7 Million
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $11.5 Million - $14.2 Million	100,000 New	100,000 $14.2 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $7.98 Million - $13.7 Million	-125,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$75.5 - $96.63 $1.89 Million - $2.42 Million	-25,000 Reduced 16.67%	125,000 $9.48 Million
Q1 2018 May 15, 2018	SELL	$56.95 - $85.19 $5.7 Million - $8.52 Million	-100,000 Reduced 40.0%	150,000 $12.1 Million
Q4 2017 Feb 14, 2018	SELL	$22.57 - $63.56 $57,192 - $161,061	-2,534 Reduced 1.0%	250,000 $15.8 Million
Q3 2017 Nov 14, 2017	BUY	$19.81 - $22.61 $5 Million - $5.71 Million	252,534	252,534 $5.71 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ghost Tree Capital, LLC with notifications on news.